dual serine/threonine and tyrosine protein kinaseGenealiases: CAKUT1 · DustyPK · HDCMD38P · RHDNS1 · RIP5 · RIPK5
Q-omics provides the consensus-scored DSTYK profile across patient tissues and cancer cell-line models. DSTYK expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DSTYK is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, DSTYK protein abundance shows 24,758 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight BLCA, LIHC, and UCEC as cancer lineages where DSTYK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DSTYK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DSTYK survival associations across molecular data types. DSTYK RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DSTYK RNA expression–survival associations across cancer types. High DSTYK expression shows unfavorable associations in BLCA, ACC, CESC, UVM and UCEC, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for DSTYK RNA expression.
This table summarizes DSTYK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 9. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DSTYK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DSTYK shows lower tumor expression in KICH, UCEC, KIRC and THCA and higher tumor expression in LIHC and HNSC. The LIHC box plot shows higher DSTYK RNA expression in tumor versus normal tissue (log2 FC = +1.285, t-test p < 0.001).
This table shows molecular features associated with DSTYK in patient tissues and cancer cell lines. In patient samples, DSTYK shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, DSTYK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
